Love it Vinay! As an Oncology Clinical Research Coordinator I see this all the time. And people don’t give patients enough credit...they can sniff out when things might not be optimal for their care when it comes to these trials. Love your book and all your clinical trial and paper reviews! Keep it up!
I suspect that the high drop out rate in the control arm was mainly due to not being assigned to Lutetium-177 and less about knowledge of a deficient control arm. This new therapy had gotten a lot of exposure in the prostate cancer community as it had been used in Germany for 10 years prior to the trial. These CRPC patients went into the trial praying they would get Lu-177 and half said nope when assigned to the control arm.
Dr. Prasad thank you for your video. All too often in Oncology we look at the final reports and do not deep dive into the trials and realize that the overall benefits touted are not always that impressive or scientifically sound.
That was most useful. I am interested in this protocol because it makes so much sense but as you've just shown, their so-called trial is at best a farce. Well begun is half done, that's one of my mottos, and this paper certainly does not begin the introduction of this novel treatment in any way that can be considered either well or ethical.
Great presentation, when I first looked into it, I thought it was dodgy too. Comparing a therapeutic vs. doing nothing seemed quite dodgy. A/Prof Prasad, given the interesting methodology used for the VISION trial. What do you take of the FDA approving the Novartis Lu-PSMA radiopharmaceutical.
Love it Vinay! As an Oncology Clinical Research Coordinator I see this all the time. And people don’t give patients enough credit...they can sniff out when things might not be optimal for their care when it comes to these trials. Love your book and all your clinical trial and paper reviews! Keep it up!
😂 I loved the coffee comment. Thank you Dr. Prasad. Please continue pointing out all these horrendous studies.
Med onc Fellow here. Love the criticism!
I suspect that the high drop out rate in the control arm was mainly due to not being assigned to Lutetium-177 and less about knowledge of a deficient control arm. This new therapy had gotten a lot of exposure in the prostate cancer community as it had been used in Germany for 10 years prior to the trial. These CRPC patients went into the trial praying they would get Lu-177 and half said nope when assigned to the control arm.
"Horrific amounts of money" 100% true! $240K for a course of treatment.
Thanks.
Great review!
Dr. Prasad thank you for your video. All too often in Oncology we look at the final reports and do not deep dive into the trials and realize that the overall benefits touted are not always that impressive or scientifically sound.
That was most useful. I am interested in this protocol because it makes so much sense but as you've just shown, their so-called trial is at best a farce. Well begun is half done, that's one of my mottos, and this paper certainly does not begin the introduction of this novel treatment in any way that can be considered either well or ethical.
Great presentation, when I first looked into it, I thought it was dodgy too. Comparing a therapeutic vs. doing nothing seemed quite dodgy.
A/Prof Prasad, given the interesting methodology used for the VISION trial. What do you take of the FDA approving the Novartis Lu-PSMA radiopharmaceutical.
Great video. Can you talk about PSMAfore trial please.
Nice to see some non-covid stuff as someone going into IM!
all great but what's the error on that 0.32%?